FIELD: biotechnology; medicine.
SUBSTANCE: group of inventions relates to biotechnology and oncology. Disclosed is an antibody or its antigen-binding fragment, which specifically binds to a BAG2 polypeptide or its fragment, its production and use. Anti-BAG2 antibody has a significant inhibitory effect on tumour growth and metastasis and can be used as a therapeutic agent in a method of treating oncological disease, which is a primary or metastatic oncological disease.
EFFECT: combination of immune checkpoint inhibitors and BAG2 antibodies has a significant inhibitory effect on a tumour in models of breast cancer, lung cancer, melanoma, colorectal cancer and pancreatic cancer.
22 cl, 9 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
